China Issues Implementing Opinions on “Artificial Intelligence + Drug Regulation”
Published 3 April 2026
Xia Yu
On 2 April 2026, the National Medical Products Administration of China (“NMPA”) issued the Implementing Opinions on “Artificial Intelligence + Drug Regulation” (“Opinions”). It is a dedicated policy formulated under the overall objective of regulatory modernization established by the Opinions of the General Office of the State Council on Comprehensively Deepening the Reform of Drug and Medical Device Regulation to Promote High-Quality Development of the Pharmaceutical Industry (issued on 3 January 2025), in light of the rapid development trend of artificial intelligence (“AI”). The Opinions aim to seize the major strategic opportunity presented by AI, promote the deep integration of AI and drug regulation, and accelerate the modernization of drug regulation.
The Opinions set two phased goals: by 2030, preliminarily establish an integrated innovation system combining drug regulation and AI, form a basic operating management mechanism for “AI + drug regulation”, create high-quality datasets, vertical large models and intelligent agents for regulatory intelligence, achieve effective application of AI in scenarios such as review and approval, inspection and supervision, testing and monitoring, and administrative services, significantly improve human-machine collaboration efficiency, and bring the digital-intelligent full-life-cycle regulatory capacity to a new level; by 2035, basically form a new intelligent drug safety governance pattern driven by digital intelligence, featuring agility, autonomous control and ecological collaboration. The Opinions is divided into four parts: general requirements, digital-intelligent empowerment of key regulatory scenarios, foundational support for “AI + drug regulation”, and implementation organization.
Core Facts: Seven Key Regulatory Scenarios and Five Foundational Support Tasks
I. Digital-Intelligent Empowerment of Key Regulatory Scenarios (Seven Directions)
1. Building a Human-Machine Collaborative Intelligent Review and Approval System
Promote the standardization and structuring of electronic submission of application dossiers, accelerate the R&D and application of large models and intelligent agents for review and approval of “drugs, cosmetics and medical devices”, covering scenarios such as intelligent product classification, task assignment, dossier review, knowledge retrieval, issue identification, report generation, and certificate issuance and delivery. Provincial NMPA branches shall collaborate with a division of labor, focusing on intelligent application in key scenarios including review of Class II medical devices, post-marketing change filings for drugs, filing of ordinary cosmetics, and approval of manufacturing and distribution licenses. Establish a human-machine collaboration mechanism featuring “digital-intelligent empowerment, manual review, and full-process traceability”.
2. Enhancing Full-Chain Intelligent Supervision Capability
R&D stage: Promote standardized governance of clinical trial data, formulate supporting guidelines such as technical guidelines for electronic recording of clinical trials and guidelines for computerized system validation.
Manufacturing stage: Improve digital-intelligent supervision mechanisms for high-risk varieties such as vaccines, blood products and special drugs; develop and deploy risk monitoring intelligent agents; dynamically monitor quality and safety risks in the manufacturing process based on real-time analysis of production process surveillance videos, images, and IoT sensing data.
Distribution and use stage: Promote digital-intelligent upgrading of the drug traceability system, achieve coding of all marketed varieties and full-process traceability from manufacturing through distribution to use; build a multi-code linkage mapping database linking drug traceability codes with commodity barcodes, medical insurance codes, etc.; formulate technical guidelines for typical application of Unique Device Identification (UDI) in the entire chain.
3. Promoting Digital-Intelligent Upgrading of the Risk Supervision System
Promote multi-source aggregation, intelligent assessment, hierarchical assignment and traceable tracking of risk clues; improve the risk consultation mechanism of “monitoring and early warning – consultation and assessment – directive disposal – tracking and review”. Launch smart drug testing initiatives, advance an integrated digital-intelligent testing system; upgrade the monitoring and evaluation system for “drugs, cosmetics and medical devices”; build an intelligent analysis and early warning system for complaints and reports; coordinate the upgrading of the online sales safety risk monitoring and public opinion monitoring systems; construct traceability risk screening and early warning models; focus on high-risk varieties and key scenarios to develop intelligent risk supervision models and draw dynamic risk profiles.
4. Promoting Intelligent and Standardised Inspection and Law Enforcement
Launch smart inspection initiatives, integrate and upgrade inspection systems, build an intensive and intelligent comprehensive inspection management platform. Based on big data from variety dossiers and credit files, conduct risk assessment to scientifically determine inspection targets, frequency and plans. Encourage provincial NMPA branches to build unified inspection and law enforcement case handling systems, strengthen AI application support (real-time query of regulated entity information, real-time input of inspection process information, intelligent detection of issue clues, automatic generation of documents and reports). Implement “code scanning for enterprise entry” to achieve “management at fingertips and inspection on the go”.
5. Enhancing Collaborative Supervision Efficiency
Rely on the smart supervision platform to build an efficient, intelligent, multi-party-linked national integrated business collaboration system, improve the list management mechanism for collaborative matters, and standardize business collaboration process rules and interface standards. Focus on key areas and links such as clinical trials, registration verification, cross-provincial contract manufacturing, and supervision of centrally procured selected products, promote intelligent assignment, full traceability and closed-loop management of cross-level and cross-regional collaborative businesses. Strengthen cross-departmental information sharing and business interaction, facilitate the collaborative development and governance of the “three medical cares” (medical services, medical insurance, and pharmaceutical supply), and support scenarios such as joint inspections, case investigation, coordination between administrative law enforcement and criminal justice, and clue handling.
6. Improving the Intelligence Level of Administrative Services
Implement the requirement of “efficiently handling one matter” on an ongoing basis, promote the construction of “AI + administrative services”. Improve the policy service knowledge base, integrate data such as policies and regulations, service guides, frequently asked questions, online consultations, user evaluations and historical processing records, optimize algorithm models, and provide services such as intelligent Q&A, intelligent guidance, intelligent form pre-filling and intelligent assistance, thereby advancing intelligent, precise and convenient administrative services.
7. Promoting Coordinated Digital-Intelligent Development of Regulation and Industry
Centering on intelligent regulatory requirements, encourage and guide the industry to accelerate digital-intelligent transformation and upgrading. Accelerate the study and formulation of guiding principles for the standardized application of AI in the pharmaceutical industry. Promote full-process digital-intelligent manufacturing and testing of high-risk varieties such as blood products and traditional Chinese medicine injections, study and formulate supporting regulatory requirements, and gradually extend to other varieties, guiding the industry to enhance full-process quality control capabilities in accordance with standards.
II. Strengthening Foundational Support for “AI + Drug Regulation” (Five Tasks)
1. Promoting the Construction of High-Quality Datasets for Drug Regulation
Adhere to the principle of “scenario-driven, urgent needs first”, advance the construction of high-quality datasets in phases and steps. Improve the national integrated drug regulatory data resource system, using variety dossiers, corporate credit files, laws and regulations databases, and typical case databases as a foundation, enhance data accuracy, consistency and usability. Formulate unified collection specifications and annotation guidelines, build a layered and categorized high-quality dataset that is dynamically updated and traceable throughout its life cycle. Under the strict premise of security and privacy, promote the compliant and efficient use of knowledge bases and high-quality datasets in scenarios such as model training, knowledge reasoning and decision support.
2. Strengthening the AI Application Support System
Coordinate the training, deployment and application of large models in the drug regulatory field. Build a large model application and algorithm management platform, formulate model application guidelines and security specifications, promote the shared construction of common technical components, and enhance model and algorithm management capabilities. Promote the deep integration of AI with business information systems, and build a multi-agent collaboration mechanism.
3. Strengthening Computing Infrastructure Construction
The NMPA shall coordinate the planning of a multi-level intelligent computing resource collaboration system, and the national and provincial levels shall promote the supply of intelligent computing resources as needed. Build a standardized, scalable intelligent computing infrastructure to meet the intelligent application needs of different network domains (internet, government extranet, government intranet). Improve cross-domain collaboration and disaster recovery capabilities, gradually form a pattern of “co-construction, co-governance and sharing”, enhance computing support capabilities, and provide continuous and stable guarantees for regulatory intelligence.
4. Building a Robust Security Protection System
Strictly implement security responsibility systems, upgrade the network security protection system, improve mechanisms for cybersecurity situational awareness, information sharing, joint assessment, threat early warning and traceability tracking, use AI technologies to enhance active network security protection capabilities, and build an intelligent, collaborative protection system. Establish a sound data security management system, define core and important data catalogues, and improve the technical system for data security protection. Strengthen AI risk monitoring and assessment, formulate algorithm transparency requirements and model validation specifications, enhance security capability building for model algorithms, data resources, infrastructure and application systems, prevent the input of classified and sensitive information into non-classified models, and promote AI applications that are compliant, transparent and trustworthy.
5. Improving the Construction and Operation Management Mechanism
Adhere to the auxiliary positioning of AI in the drug regulatory field, clearly define functional boundaries and responsible entities, and avoid deployment without review, fragmented construction and redundant construction. Establish a dedicated mechanism to coordinate AI application governance in drug regulation, formulate management systems for “AI + drug regulation”, and clarify division of responsibilities and work procedures. Improve the filing management system for models and algorithms, formulate basic guidelines and technical specifications, and carry out validation and assessment of effectiveness and reliability for models and their auxiliary applications. Strengthen the management of data resources such as training data, fine-tuning data and knowledge bases, ensuring legal sources, accurate content, compliant use and full traceability. Explore authorized operation of public data in drug regulation, build public data zones, and promote the development and utilization of drug regulatory public data by scenario and by authorization.
Comments
AI is reshaping the legal framework for drug regulation, moving from “selective supervision” to “systemic embedding”. The Opinions are not a simple upgrade of technical tools but rather an effort to use AI as the underlying logic for restructuring the exercise of regulatory power. Human-machine collaboration in review and approval, intelligent document generation in inspection and law enforcement, and model-based early warning in risk supervision – these scenarios entail a partial delegation of administrative discretion to algorithms. Notably, when an AI assists in making decisions such as denial of approval, suspension of production, or administrative penalty, how should liability be allocated? The Opinions propose the principles of “auxiliary positioning” and “manual review”, but legal issues such as the substantive standards for review, algorithm explainability requirements, and the right to information and remedies of the counterparty have not yet been refined. This will become a focal point of controversy at the intersection of administrative procedure law and drug administration law in the future.
The Opinions require the construction of high-quality datasets, emphasizing legal source, accurate content, compliant use and full traceability of data. For pharmaceutical enterprises, data compliance will become a new rigid cost. This means that clinical trial data must be governed in accordance with technical guidelines for electronic recording and computerized system validation; otherwise, data mutual recognition in review and approval may be affected. With respect to manufacturing data, surveillance videos and IoT sensing data from the production process of high-risk varieties will be analyzed in real time for risk monitoring, and enterprises must ensure that data is authentic, complete and unaltered. As for traceability data, once the traceability code is linked with multiple codes including the medical insurance code, any anomaly in the data (e.g., a distribution early warning) will trigger regulatory action. Enterprises should promptly establish internal data governance systems, clarify data asset catalogues, and assess the commercial risks of data sharing and authorized operation.
The Opinions explicitly require the formulation of algorithm transparency requirements and model validation specifications, and mandate the filing of models and algorithms. This draws on the regulatory approach of the Cyberspace Administration of China’s Interim Measures for the Management of Generative Artificial Intelligence Services, but is more stringent in the drug regulatory field. Enterprises using AI for quality management, adverse reaction monitoring, pharmacovigilance and other activities may have their internal algorithms brought within the filing scope. “Algorithm transparency” and “model filing” will become new types of compliance obligations. Relevant enterprises should proactively identify which AI applications fall within the regulatory scope, prepare technical documentation, validation reports and transparency statements, and establish compliance review processes for algorithm changes.
The Opinions emphasize the autonomous control of computing infrastructure, require “full traceability” of data resource management, and explicitly prevent the input of classified and sensitive information into non-classified models. For multinational pharmaceutical companies, if their globally unified AI quality management or clinical data analysis platform involves cross-border data transfer, they may face conflicts with the requirements of the Opinions. It is recommended that such companies assess in advance whether they need to deploy independent computing resources and model instances within China, and whether their Domestic Responsible Party has sufficient data governance authority.
The Opinions explicitly promote the full-process digital-intelligent manufacturing and testing of high-risk varieties such as blood products and traditional Chinese medicine injections, and will study and formulate supporting regulatory requirements, gradually extending to other varieties. This means that digital intelligence for high-risk varieties will become a market access threshold. In the future, if an enterprise has not achieved full-chain digital intelligence of its production process (e.g., integration of MES system with the regulatory platform), it may fail to pass compliance inspections or renew its manufacturing license. This signals a turning point from “encouragement” to “mandatory” requirement.
The Opinions propose, for the first time in the drug regulatory field, exploring authorized operation of public data and building public data zones. This means that public data held by the NMPA, such as variety dossiers, corporate credit files, and adverse reaction data, may in the future be opened to compliant enterprises through authorization. This creates new business models for data analysis service providers, insurance institutions, and pharmaceutical consulting firms, but also requires attention to liability clauses, data use restrictions and benefit-sharing mechanisms in authorization agreements. In Closing The Opinions signify that China’s drug regulation has entered a new stage driven by “digital intelligence”. Relevant enterprises should closely monitor the subsequent issuance of supporting guidelines (such as algorithm validation specifications, data annotation guidelines, and detailed rules for authorized operation), and conduct internal technical compliance audits in advance. The digital-intelligent coordination between regulation and industry will ultimately reshape the competitive landscape of the pharmaceutical industry – data capability and algorithm governance level will become the next core competitive advantage after the quality system.
The Opinions set two phased goals: by 2030, preliminarily establish an integrated innovation system combining drug regulation and AI, form a basic operating management mechanism for “AI + drug regulation”, create high-quality datasets, vertical large models and intelligent agents for regulatory intelligence, achieve effective application of AI in scenarios such as review and approval, inspection and supervision, testing and monitoring, and administrative services, significantly improve human-machine collaboration efficiency, and bring the digital-intelligent full-life-cycle regulatory capacity to a new level; by 2035, basically form a new intelligent drug safety governance pattern driven by digital intelligence, featuring agility, autonomous control and ecological collaboration. The Opinions is divided into four parts: general requirements, digital-intelligent empowerment of key regulatory scenarios, foundational support for “AI + drug regulation”, and implementation organization.
Core Facts: Seven Key Regulatory Scenarios and Five Foundational Support Tasks
I. Digital-Intelligent Empowerment of Key Regulatory Scenarios (Seven Directions)
1. Building a Human-Machine Collaborative Intelligent Review and Approval System
Promote the standardization and structuring of electronic submission of application dossiers, accelerate the R&D and application of large models and intelligent agents for review and approval of “drugs, cosmetics and medical devices”, covering scenarios such as intelligent product classification, task assignment, dossier review, knowledge retrieval, issue identification, report generation, and certificate issuance and delivery. Provincial NMPA branches shall collaborate with a division of labor, focusing on intelligent application in key scenarios including review of Class II medical devices, post-marketing change filings for drugs, filing of ordinary cosmetics, and approval of manufacturing and distribution licenses. Establish a human-machine collaboration mechanism featuring “digital-intelligent empowerment, manual review, and full-process traceability”.
2. Enhancing Full-Chain Intelligent Supervision Capability
R&D stage: Promote standardized governance of clinical trial data, formulate supporting guidelines such as technical guidelines for electronic recording of clinical trials and guidelines for computerized system validation.
Manufacturing stage: Improve digital-intelligent supervision mechanisms for high-risk varieties such as vaccines, blood products and special drugs; develop and deploy risk monitoring intelligent agents; dynamically monitor quality and safety risks in the manufacturing process based on real-time analysis of production process surveillance videos, images, and IoT sensing data.
Distribution and use stage: Promote digital-intelligent upgrading of the drug traceability system, achieve coding of all marketed varieties and full-process traceability from manufacturing through distribution to use; build a multi-code linkage mapping database linking drug traceability codes with commodity barcodes, medical insurance codes, etc.; formulate technical guidelines for typical application of Unique Device Identification (UDI) in the entire chain.
3. Promoting Digital-Intelligent Upgrading of the Risk Supervision System
Promote multi-source aggregation, intelligent assessment, hierarchical assignment and traceable tracking of risk clues; improve the risk consultation mechanism of “monitoring and early warning – consultation and assessment – directive disposal – tracking and review”. Launch smart drug testing initiatives, advance an integrated digital-intelligent testing system; upgrade the monitoring and evaluation system for “drugs, cosmetics and medical devices”; build an intelligent analysis and early warning system for complaints and reports; coordinate the upgrading of the online sales safety risk monitoring and public opinion monitoring systems; construct traceability risk screening and early warning models; focus on high-risk varieties and key scenarios to develop intelligent risk supervision models and draw dynamic risk profiles.
4. Promoting Intelligent and Standardised Inspection and Law Enforcement
Launch smart inspection initiatives, integrate and upgrade inspection systems, build an intensive and intelligent comprehensive inspection management platform. Based on big data from variety dossiers and credit files, conduct risk assessment to scientifically determine inspection targets, frequency and plans. Encourage provincial NMPA branches to build unified inspection and law enforcement case handling systems, strengthen AI application support (real-time query of regulated entity information, real-time input of inspection process information, intelligent detection of issue clues, automatic generation of documents and reports). Implement “code scanning for enterprise entry” to achieve “management at fingertips and inspection on the go”.
5. Enhancing Collaborative Supervision Efficiency
Rely on the smart supervision platform to build an efficient, intelligent, multi-party-linked national integrated business collaboration system, improve the list management mechanism for collaborative matters, and standardize business collaboration process rules and interface standards. Focus on key areas and links such as clinical trials, registration verification, cross-provincial contract manufacturing, and supervision of centrally procured selected products, promote intelligent assignment, full traceability and closed-loop management of cross-level and cross-regional collaborative businesses. Strengthen cross-departmental information sharing and business interaction, facilitate the collaborative development and governance of the “three medical cares” (medical services, medical insurance, and pharmaceutical supply), and support scenarios such as joint inspections, case investigation, coordination between administrative law enforcement and criminal justice, and clue handling.
6. Improving the Intelligence Level of Administrative Services
Implement the requirement of “efficiently handling one matter” on an ongoing basis, promote the construction of “AI + administrative services”. Improve the policy service knowledge base, integrate data such as policies and regulations, service guides, frequently asked questions, online consultations, user evaluations and historical processing records, optimize algorithm models, and provide services such as intelligent Q&A, intelligent guidance, intelligent form pre-filling and intelligent assistance, thereby advancing intelligent, precise and convenient administrative services.
7. Promoting Coordinated Digital-Intelligent Development of Regulation and Industry
Centering on intelligent regulatory requirements, encourage and guide the industry to accelerate digital-intelligent transformation and upgrading. Accelerate the study and formulation of guiding principles for the standardized application of AI in the pharmaceutical industry. Promote full-process digital-intelligent manufacturing and testing of high-risk varieties such as blood products and traditional Chinese medicine injections, study and formulate supporting regulatory requirements, and gradually extend to other varieties, guiding the industry to enhance full-process quality control capabilities in accordance with standards.
II. Strengthening Foundational Support for “AI + Drug Regulation” (Five Tasks)
1. Promoting the Construction of High-Quality Datasets for Drug Regulation
Adhere to the principle of “scenario-driven, urgent needs first”, advance the construction of high-quality datasets in phases and steps. Improve the national integrated drug regulatory data resource system, using variety dossiers, corporate credit files, laws and regulations databases, and typical case databases as a foundation, enhance data accuracy, consistency and usability. Formulate unified collection specifications and annotation guidelines, build a layered and categorized high-quality dataset that is dynamically updated and traceable throughout its life cycle. Under the strict premise of security and privacy, promote the compliant and efficient use of knowledge bases and high-quality datasets in scenarios such as model training, knowledge reasoning and decision support.
2. Strengthening the AI Application Support System
Coordinate the training, deployment and application of large models in the drug regulatory field. Build a large model application and algorithm management platform, formulate model application guidelines and security specifications, promote the shared construction of common technical components, and enhance model and algorithm management capabilities. Promote the deep integration of AI with business information systems, and build a multi-agent collaboration mechanism.
3. Strengthening Computing Infrastructure Construction
The NMPA shall coordinate the planning of a multi-level intelligent computing resource collaboration system, and the national and provincial levels shall promote the supply of intelligent computing resources as needed. Build a standardized, scalable intelligent computing infrastructure to meet the intelligent application needs of different network domains (internet, government extranet, government intranet). Improve cross-domain collaboration and disaster recovery capabilities, gradually form a pattern of “co-construction, co-governance and sharing”, enhance computing support capabilities, and provide continuous and stable guarantees for regulatory intelligence.
4. Building a Robust Security Protection System
Strictly implement security responsibility systems, upgrade the network security protection system, improve mechanisms for cybersecurity situational awareness, information sharing, joint assessment, threat early warning and traceability tracking, use AI technologies to enhance active network security protection capabilities, and build an intelligent, collaborative protection system. Establish a sound data security management system, define core and important data catalogues, and improve the technical system for data security protection. Strengthen AI risk monitoring and assessment, formulate algorithm transparency requirements and model validation specifications, enhance security capability building for model algorithms, data resources, infrastructure and application systems, prevent the input of classified and sensitive information into non-classified models, and promote AI applications that are compliant, transparent and trustworthy.
5. Improving the Construction and Operation Management Mechanism
Adhere to the auxiliary positioning of AI in the drug regulatory field, clearly define functional boundaries and responsible entities, and avoid deployment without review, fragmented construction and redundant construction. Establish a dedicated mechanism to coordinate AI application governance in drug regulation, formulate management systems for “AI + drug regulation”, and clarify division of responsibilities and work procedures. Improve the filing management system for models and algorithms, formulate basic guidelines and technical specifications, and carry out validation and assessment of effectiveness and reliability for models and their auxiliary applications. Strengthen the management of data resources such as training data, fine-tuning data and knowledge bases, ensuring legal sources, accurate content, compliant use and full traceability. Explore authorized operation of public data in drug regulation, build public data zones, and promote the development and utilization of drug regulatory public data by scenario and by authorization.
Comments
AI is reshaping the legal framework for drug regulation, moving from “selective supervision” to “systemic embedding”. The Opinions are not a simple upgrade of technical tools but rather an effort to use AI as the underlying logic for restructuring the exercise of regulatory power. Human-machine collaboration in review and approval, intelligent document generation in inspection and law enforcement, and model-based early warning in risk supervision – these scenarios entail a partial delegation of administrative discretion to algorithms. Notably, when an AI assists in making decisions such as denial of approval, suspension of production, or administrative penalty, how should liability be allocated? The Opinions propose the principles of “auxiliary positioning” and “manual review”, but legal issues such as the substantive standards for review, algorithm explainability requirements, and the right to information and remedies of the counterparty have not yet been refined. This will become a focal point of controversy at the intersection of administrative procedure law and drug administration law in the future.
The Opinions require the construction of high-quality datasets, emphasizing legal source, accurate content, compliant use and full traceability of data. For pharmaceutical enterprises, data compliance will become a new rigid cost. This means that clinical trial data must be governed in accordance with technical guidelines for electronic recording and computerized system validation; otherwise, data mutual recognition in review and approval may be affected. With respect to manufacturing data, surveillance videos and IoT sensing data from the production process of high-risk varieties will be analyzed in real time for risk monitoring, and enterprises must ensure that data is authentic, complete and unaltered. As for traceability data, once the traceability code is linked with multiple codes including the medical insurance code, any anomaly in the data (e.g., a distribution early warning) will trigger regulatory action. Enterprises should promptly establish internal data governance systems, clarify data asset catalogues, and assess the commercial risks of data sharing and authorized operation.
The Opinions explicitly require the formulation of algorithm transparency requirements and model validation specifications, and mandate the filing of models and algorithms. This draws on the regulatory approach of the Cyberspace Administration of China’s Interim Measures for the Management of Generative Artificial Intelligence Services, but is more stringent in the drug regulatory field. Enterprises using AI for quality management, adverse reaction monitoring, pharmacovigilance and other activities may have their internal algorithms brought within the filing scope. “Algorithm transparency” and “model filing” will become new types of compliance obligations. Relevant enterprises should proactively identify which AI applications fall within the regulatory scope, prepare technical documentation, validation reports and transparency statements, and establish compliance review processes for algorithm changes.
The Opinions emphasize the autonomous control of computing infrastructure, require “full traceability” of data resource management, and explicitly prevent the input of classified and sensitive information into non-classified models. For multinational pharmaceutical companies, if their globally unified AI quality management or clinical data analysis platform involves cross-border data transfer, they may face conflicts with the requirements of the Opinions. It is recommended that such companies assess in advance whether they need to deploy independent computing resources and model instances within China, and whether their Domestic Responsible Party has sufficient data governance authority.
The Opinions explicitly promote the full-process digital-intelligent manufacturing and testing of high-risk varieties such as blood products and traditional Chinese medicine injections, and will study and formulate supporting regulatory requirements, gradually extending to other varieties. This means that digital intelligence for high-risk varieties will become a market access threshold. In the future, if an enterprise has not achieved full-chain digital intelligence of its production process (e.g., integration of MES system with the regulatory platform), it may fail to pass compliance inspections or renew its manufacturing license. This signals a turning point from “encouragement” to “mandatory” requirement.
The Opinions propose, for the first time in the drug regulatory field, exploring authorized operation of public data and building public data zones. This means that public data held by the NMPA, such as variety dossiers, corporate credit files, and adverse reaction data, may in the future be opened to compliant enterprises through authorization. This creates new business models for data analysis service providers, insurance institutions, and pharmaceutical consulting firms, but also requires attention to liability clauses, data use restrictions and benefit-sharing mechanisms in authorization agreements. In Closing The Opinions signify that China’s drug regulation has entered a new stage driven by “digital intelligence”. Relevant enterprises should closely monitor the subsequent issuance of supporting guidelines (such as algorithm validation specifications, data annotation guidelines, and detailed rules for authorized operation), and conduct internal technical compliance audits in advance. The digital-intelligent coordination between regulation and industry will ultimately reshape the competitive landscape of the pharmaceutical industry – data capability and algorithm governance level will become the next core competitive advantage after the quality system.